{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:44:30Z","timestamp":1793742270268,"version":"4.6.1"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2019,11,1]]},"DOI":"10.1001\/jamaneurol.2019.2137","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T11:00:57Z","timestamp":1565607657000},"page":"1359","source":"Crossref","is-referenced-by-count":193,"title":["Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years"],"prefix":"10.1001","volume":"76","author":[{"given":"Ester","family":"Cant\u00f3","sequence":"first","affiliation":[{"name":"Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Barro","sequence":"additional","affiliation":[{"name":"Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy J.","family":"Caillier","sequence":"additional","affiliation":[{"name":"Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Michalak","sequence":"additional","affiliation":[{"name":"Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Bove","sequence":"additional","affiliation":[{"name":"Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davorka","family":"Tomic","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Santaniello","sequence":"additional","affiliation":[{"name":"Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter A.","family":"H\u00e4ring","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Hollenbach","sequence":"additional","affiliation":[{"name":"Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland G.","family":"Henry","sequence":"additional","affiliation":[{"name":"Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A. C.","family":"Cree","sequence":"additional","affiliation":[{"name":"Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[{"name":"Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland"},{"name":"Department of Biomedical Engineering, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Leppert","sequence":"additional","affiliation":[{"name":"Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Hauser","sequence":"additional","affiliation":[{"name":"Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Benkert","sequence":"additional","affiliation":[{"name":"Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge R.","family":"Oksenberg","sequence":"additional","affiliation":[{"name":"Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[{"name":"Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"noi190056r1","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/joim.2014.275.issue-4","article-title":"Established and novel disease-modifying treatments in multiple sclerosis.","volume":"275","author":"Cross","year":"2014","journal-title":"J Intern Med"},{"issue":"2","key":"noi190056r2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S1474-4422(14)70231-5","article-title":"Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.","volume":"14","author":"Feinstein","year":"2015","journal-title":"Lancet Neurol"},{"issue":"1","key":"noi190056r3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.clim.2015.06.015","article-title":"Biomarkers in multiple sclerosis.","volume":"161","author":"Housley","year":"2015","journal-title":"Clin Immunol"},{"key":"noi190056r4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/ane.2017.136.issue-S201","article-title":"The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.","volume":"136","author":"Reuwer","year":"2017","journal-title":"Acta Neurol Scand"},{"issue":"9451","key":"noi190056r5","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"noi190056r6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/(ISSN)1531-8249","article-title":"Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.","volume":"48","author":"Bjartmar","year":"2000","journal-title":"Ann Neurol"},{"issue":"2","key":"noi190056r7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/jnnp.2004.043315","article-title":"Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.","volume":"76","author":"Petzold","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"noi190056r8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/jnnp.64.3.402","article-title":"Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.","volume":"64","author":"Lycke","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"noi190056r9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"noi190056r10","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1177\/1352458516645206","article-title":"Elevated CSF neurofilament proteins predict brain atrophy: a 15-year follow-up study.","volume":"22","author":"Petzold","year":"2016","journal-title":"Mult Scler"},{"issue":"21","key":"noi190056r11","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","article-title":"Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration.","volume":"89","author":"Weston","year":"2017","journal-title":"Neurology"},{"issue":"5-6","key":"noi190056r12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/21678421.2017.1281962","article-title":"Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival.","volume":"18","author":"Skillb\u00e4ck","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"8","key":"noi190056r13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis.","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol"},{"issue":"6","key":"noi190056r14","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.v81.6","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis.","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol"},{"issue":"12","key":"noi190056r15","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1177\/1352458515623365","article-title":"Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.","volume":"22","author":"Kuhle","year":"2016","journal-title":"Mult Scler"},{"issue":"9","key":"noi190056r16","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000003653","article-title":"Serum neurofilament is associated with progression of brain atrophy and disability in early MS.","volume":"88","author":"Kuhle","year":"2017","journal-title":"Neurology"},{"key":"noi190056r17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","article-title":"Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study.","volume":"3","author":"Gissl\u00e9n","year":"2015","journal-title":"EBioMedicine"},{"issue":"4","key":"noi190056r18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.24747","article-title":"Long-term evolution of multiple sclerosis disability in the treatment era.","volume":"80","author":"Cree","year":"2016","journal-title":"Ann Neurol"},{"issue":"1","key":"noi190056r19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/(ISSN)1531-8249","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann Neurol"},{"issue":"11","key":"noi190056r20","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"15","key":"noi190056r21","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1212\/WNL.0b013e3181a0fe3f","article-title":"Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.","volume":"72","author":"Teunissen","year":"2009","journal-title":"Neurology"},{"issue":"9","key":"noi190056r22","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1212\/01.WNL.0000142988.49341.D1","article-title":"Neurofilament and glial fibrillary acidic protein in multiple sclerosis.","volume":"63","author":"Norgren","year":"2004","journal-title":"Neurology"},{"issue":"14","key":"noi190056r23","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1212\/WNL.0b013e31821432ff","article-title":"Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.","volume":"76","author":"Kuhle","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"noi190056r24","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1352458512458010","article-title":"CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome.","volume":"19","author":"Khalil","year":"2013","journal-title":"Mult Scler"},{"issue":"8","key":"noi190056r25","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"noi190056r26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.msard.2017.01.007","article-title":"Is multiple sclerosis a length-dependent central axonopathy? the case for therapeutic lag and the asynchronous progressive MS hypotheses.","volume":"12","author":"Giovannoni","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"noi190056r27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/ana.v69.1","article-title":"Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.","volume":"69","author":"Gunnarsson","year":"2011","journal-title":"Ann Neurol"},{"issue":"1","key":"noi190056r28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/1352458513490544","article-title":"Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.","volume":"20","author":"Axelsson","year":"2014","journal-title":"Mult Scler"},{"issue":"16","key":"noi190056r29","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1212\/WNL.0000000000001491","article-title":"Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.","volume":"84","author":"Kuhle","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"noi190056r30","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/jnc.2017.141.issue-2","article-title":"Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.","volume":"141","author":"Novakova","year":"2017","journal-title":"J Neurochem"},{"issue":"8","key":"noi190056r31","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1177\/1352458517715132","article-title":"Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.","volume":"24","author":"Piehl","year":"2018","journal-title":"Mult Scler"},{"issue":"22","key":"noi190056r32","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"noi190056r33","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1212\/WNL.0000000000003085","article-title":"Neurofilament light chain level is a weak risk factor for the development of MS.","volume":"87","author":"Arrambide","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"noi190056r34","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"issue":"12","key":"noi190056r35","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acn3.2018.5.issue-12","article-title":"Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.","volume":"5","author":"Chitnis","year":"2018","journal-title":"Ann Clin Transl Neurol"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2747563\/jamaneurology_cant_2019_oi_190056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T11:01:10Z","timestamp":1573470070000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2747563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2019.2137","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}